Contents
29 January 2020
Vol 12, Issue 528
Vol 12, Issue 528
Research Articles
- A dual apolipoprotein C-II mimetic–apolipoprotein C-III antagonist peptide lowers plasma triglycerides
An apolipoprotein C-II peptide mimetic for the treatment of hypertriglyceridemia activates lipoprotein lipase and blocks apolipoprotein C-III.
- Mapping global variation in dengue transmission intensity
A downloadable high-resolution map of global dengue transmission intensity helps predict the potential impact of control strategies.
- Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes
Targeting the G protein–coupled estrogen receptor GPER with a selective agonist ameliorates obesity and diabetes in mice.
- Immune correlates of tuberculosis disease and risk translate across species
Comparison of human TB gene signature to mouse and macaque models reveals common immune correlates of TB disease and risk.
- Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal
Persistent mixed chimerism protects against rejection of HLA-matched and mismatched kidney transplants without graft-versus-host disease.
- Different human resting memory CD4+ T cell subsets show similar low inducibility of latent HIV-1 proviruses
Latent replication-competent HIV-1 proviruses in different memory T cell subsets show no differences in viral gene transcription after T cell activation.
Editors' Choice
- Airway macrophages reveal their origins
Airway macrophages are derived from recipient circulating monocytes after transplant.
- Unfolding the mystery of UPR in astrocytes
Activation of the unfolded protein response in astrocytes leads to a distinct reactive state detrimental to neuronal health in prion disease.
- Immunomodulation in the front, bone-binding in the back
Zoledronic acid–tethered nanoparticles bind remodeling bone, polarize macrophages, and reduce osteoclasts to prevent breast cancer–induced osteolysis.
About The Cover
ONLINE COVER Taming Triglycerides. Elevated plasma lipids are associated with risk of cardiovascular disease. This image shows a snapshot of the simulated interaction between a peptide with therapeutic potential (D6PV, blue and red ribbon structures) and a trilayer of triglyceride-rich lipids. Wolska et al. developed D6PV to reduce triglycerides. By mimicking apolipoprotein C-II and antagonizing apolipoprotein C-III, D6PV induced lipolysis in plasma from patients with hypertriglyceridemia ex vivo. This dual-function lipid-lowering peptide also reduced low-density lipoproteins, triglycerides, and apolipoprotein C-III in mouse models, suggesting it could help to treat hypertriglyceridemia. [CREDIT: WOLSKA ET AL./SCIENCE TRANSLATIONAL MEDICINE]
